en · de · es
sr9009-notes.peptides1004.com › Wiki › Sr9009 Handling And Quality Control — Research Overview

Sr9009 Handling And Quality Control — Research Overview

By Editorial Desk · published 2025-07-21 · last reviewed 2025-09-01 · Wiki

Everything below concerns research chemical. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2025-09-01. Numbers and descriptions here follow the published literature rather than marketing material.

SR9009 Handling and Quality Control

SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.

SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.

Background and Mechanism

Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.

Sr9009 at a glance

PropertyValueNotes
SynonymsSR9009; StenabolicStenabolic is an informal name
Common formCrystalline powderSupplied in milligram to gram quantities
Long-term storage-20 °C, desiccated, protected from lightReduces degradation
Detection techniqueLC-MS/MSCommon in anti-doping and research analysis
Regulatory statusProhibited in sport by WADANot approved for human therapeutic use

Detection, Regulation, and Misconceptions

Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.

Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.

Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.

Related pages on this site

Background and Pharmacological Mechanism

SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.

SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.

Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.

Handling, Analysis, and Regulation

Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.

Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.

Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.

Analytical Detection and Stability

Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.

Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.

Reference notes

=== Shape === Circulating inactivated platelets are biconvex discoid (lens-shaped) structures, 2–3 μm in greatest diameter. Activated platelets have cell membrane projections covering their surface. In a first approximation, the shape can be considered similar to oblate spheroids, with a semiaxis ratio of 2 to 8. This approximation can be used to model the hydrodynamic and optical properties of a population, as well as to restore the geometric parameters of individual measured platelets by flow cytometry. More accurate biophysical models of platelet surface morphology that model its shape from first principles make it possible to obtain a more realistic platelet geometry in a calm and activated state.

== Other activities == As an actress, Pansino appeared on Season 2 of VH1's Scream Queens, a reality series in which the prize was a role in one of the Saw films; she finished in 9th place. Following this, Pansino appeared in small roles on shows such as Parks and Recreation and CSI: Crime Scene Investigation. She voiced the role of Violet in the animated web series Broken Quest in 2013. In 2015, she made a cameo in the music video for "Dessert" by Dawin ft. Silentó. In 2016, she had a recurring voice role on the television series Emo Dad and also guest starred in the Disney Channel series Bizaardvark as herself. Pansino starred on the third season of YouTube Red's Escape the Night as The Jetsetter in 2018, the fourth season as The Socialite in 2019, and the later three-episode follow-up series as The Fitness Instructor in 2025. Pansino and the rest of the cast for both the third and fourth seasons were nominated for Streamy Awards. In 2023, she guest starred as a wedding planner on NCIS: Los Angeles, which she described as a "dream come true." Pansino is a classically trained singer. She released her debut single entitled, "Perfect Together", in 2015. Produced by Kurt Hugo Schneider, it was initially released as a single on iTunes, but a music video was released later the same year; as of 2019, it has over 20 million views. She has continued to post covers of popular songs on her YouTube channel, notably of songs like "Part of Your World" from the Disney movie The Little Mermaid.

== External links == FDA Summary of Juvéderm’s effectiveness and safety FDA: Physician’s instructions (intended use, contraindications, warnings and dosage) for using Juvéderm Raspaldo, Hervé; Gassia, Véronique; Niforos, François-Rene; Michaud, Thierry (2012). "Global, 3-dimensional approach to natural rejuvenation: Part 1 - recommendations for volume restoration and the periocular area". Journal of Cosmetic Dermatology. 11 (4): 279–289. doi:10.1111/jocd.12003. PMID 23174051.

Aristotle is saying that at this stage the body is still growing; it is best for sexual activity to begin when its growth is 'no longer abundant', for when the body is more or less at full height, the transformation of nourishment into semen does not drain the body of needed material." Additionally, "Aristotle tells us that the region round the eyes was the region of the head most fruitful of seed ("most seedy" σπερματικώτατος), pointing to generally recognised effects upon the eyes of sexual indulgence and to practices which imply that seed comes from liquid in the region of the eyes." This may be explained by the belief of the Pythagoreans that "semen is a drop of the brain [τὸ δε σπέρμα εἶναι σταγόνα ἐγκέφαλου]." Greek Stoic philosophy conceived of the Logos spermatikos ("seminal word") as the principle of active reason that fecundated passive matter. The Jewish philosopher Philo similarly spoke in sexual terms of the Logos as the masculine principle of reason that sowed seeds of virtue in the feminine soul. The Christian Platonist Clement of Alexandria likened the Logos to physical blood as the "substance of the soul", and noted that some held "that the animal semen is substantially foam of its blood". Clement reflected an early Christian view that "the seed ought not be wasted nor scattered thoughtlessly nor sown in a way it cannot grow." Women were believed to have their own version, which was stored in the womb and released during climax. Retention was believed to cause female hysteria.

=== Fragment based (group contribution) === Analogously, the "partition coefficient"—a measurement of differential solubility and itself a component of QSAR predictions—can be predicted either by atomic methods (known as "XLogP" or "ALogP") or by chemical fragment methods (known as "CLogP" and other variations). It has been shown that the logP of compound can be determined by the sum of its fragments; fragment-based methods are generally accepted as better predictors than atomic-based methods. Fragmentary values have been determined statistically, based on empirical data for known logP values. This method gives mixed results and is generally not trusted to have accuracy of more than ±0.1 units. Group or fragment-based QSAR is also known as GQSAR. GQSAR allows flexibility to study various molecular fragments of interest in relation to the variation in biological response. The molecular fragments could be substituents at various substitution sites in congeneric set of molecules or could be on the basis of pre-defined chemical rules in case of non-congeneric sets. GQSAR also considers cross-terms fragment descriptors, which could be helpful in identification of key fragment interactions in determining variation of activity. Lead discovery using fragnomics is an emerging paradigm. In this context FB-QSAR proves to be a promising strategy for fragment library design and in fragment-to-lead identification endeavours. An advanced approach on fragment or group-based QSAR based on the concept of pharmacophore-similarity is developed.

Sources: en.wikipedia.org

Reference notes

Nanomaterials describe, in principle, materials of which a single unit is sized (in at least one dimension) between 1 and 1000 nanometers (10−9 meter), but is usually 1 nm – 100 nm. Nanomaterials research takes a materials science based approach to nanotechnology, using advances in materials metrology and synthesis, which have been developed in support of microfabrication research. Materials with structure at the nanoscale often have unique optical, electronic, or mechanical properties. The field of nanomaterials is loosely organized, like the traditional field of chemistry, into organic (carbon-based) nanomaterials, such as fullerenes, and inorganic nanomaterials based on other elements, such as silicon. Examples of nanomaterials include fullerenes, carbon nanotubes, nanocrystals, etc.

=== Altered metabolism === Diabetes mellitus is a metabolic disorder, and hence the defects observed in diabetic wound healing are thought to be the result of altered protein and lipid metabolism and thereby abnormal granulation tissue formation. Increased glucose levels in the body end up in uncontrolled covalent bonding of aldose sugars to a protein or lipid without any normal glycosylation enzymes. These stable products then accumulate over the surface of cell membranes, structural proteins and circulating proteins. These products are called advanced glycation endproducts (AGEs) or Amadori products. Formation of AGEs occurs on extracellular matrix proteins with a slow turnover rate. AGEs alter the properties of matrix proteins such as collagen, vitronectin, and laminin through AGE-AGE intermolecular covalent bonds or cross-linking. AGE cross-linking on type I collagen and elastin results in increased stiffness. AGEs are also known to increase the synthesis of type III collagen that forms the granulation tissue. AGEs on laminin result in reduced binding to type IV collagen in the basement membrane, reduced polymer elongation, and reduced binding of heparan sulfate proteoglycan.

== Contraindications == This product should not be used to cover a large area for anesthetic affect causing an adverse reaction. The liquid and other forms of Cetacaine should not be administered via injection or used under dentures, on eyes or with patients with a cholinesterase deficiency.

=== ADHD medication === CEO of the ASHP Dr. Paul Abramowitz reported that shortages in Adderall medication developed to a point where they were "demand-driven". Shortages beginning in October 2022 were caused or exacerbated by limited prescriptions amounts controlled by the Drug Enforcement Administration, coupled with over-diagnosis of ADHD and overprescription of Adderall. Scarcity continued in 2024 as a result of continually increased demand and supply chain problems, despite increases in production and distribution of Adderall. Patients and healthcare providers have expressed concerns about the impact on treatment plans for ADHD and narcolepsy, as many individuals rely on this medication for managing their symptoms.

These fractions also contained toxins readily separable from the short-chain isotoxin by preparative reverse-phase chromatography. Amino-acid sequencing of the first 28 residues indicated that both toxins were long-chain neurotoxins with identical N-termini. The LD50 of long-chain neurotoxins 2 from N. a. annulata and N. christyi venoms were 0.086 and 0.090 mg/kg, respectively. The venoms of these little-known elapids have some of the lowest intraperitoneal LD50 values of any African Naja species studied thus far, and have high concentrations of potent postsynaptic neurotoxins.

Sources: en.wikipedia.org

Frequently asked questions

How is SR9009 detected in samples?

Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.

What does research-grade purity mean?

Research-grade purity indicates a supplier's measured percentage of the intended compound. It does not guarantee safety, sterility, or suitability for human consumption. Buyers should request a certificate of analysis with chromatograms and test methods.

Why is SR9009 banned in sport?

Sports regulators prohibit SR9009 because it is a non-approved substance with potential performance-altering effects. Its presence can be detected in anti-doping testing. Athletes are responsible for substances found in their samples.

What is SR9009?

SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.

Network